1
|
Ireland EM, Heller J, Leister EM, Padula AM. Reduced incidence of tick paralysis cases in dogs and cats at two emergency clinics in South-East Queensland since 2015: new generation prophylactics as possible explanatory variables. Aust Vet J 2023; 101:356-365. [PMID: 37503789 DOI: 10.1111/avj.13269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Revised: 02/16/2023] [Accepted: 07/08/2023] [Indexed: 07/29/2023]
Abstract
INTRODUCTION This study aimed to determine the incidence of canine and feline tick paralysis cases presenting to two veterinary emergency hospitals before and after the introduction of new generation prophylactic acaricides. METHODS This was a retrospective study, investigating the number of tick paralysis cases presenting to two emergency and critical care veterinary hospitals in South-East Queensland, from 2008 to 2021. A total of 10,914 dogs and 3696 cats were included over the course of the study. To assess if the introduction of new generation prophylactics in 2015 has coincided with any variation in case numbers, data for each species were analysed graphically and numerically in the first instance, then interrupted time series analyses were performed for the dog and cat data independently. RESULTS Accounting for seasonal and climatic variation, we estimated a 54.8% reduction in dog (95% CI 45.3%-62.7%) and 44% reduction in cat (95% CI 19.5%-46%) tick paralysis cases presenting to these two clinics. This reduction corresponded with the timing of new generation prophylactic agents being introduced, including isoxazolines and imidacloprid/flumethrin impregnated collars. CONCLUSION In the population studied, a significant reduction in the incidence of tick paralysis cases treated by veterinarians has occurred from 2015 onwards and was found to be associated with the timing of the release of new generation acaricidal products.
Collapse
Affiliation(s)
- E M Ireland
- Animal Emergency Service, Underwood, Australia
- Pet Intensive Care Unit, Underwood, Australia
| | - J Heller
- Heller Consulting, Wagga Wagga, NSW, Australia
- Gulbali Research Institute, Charles Sturt University, Wagga Wagga, NSW, Australia
- School of Agricultural, Environmental and Veterinary Sciences, Charles Sturt University, Wagga Wagga, NSW, Australia
| | - E M Leister
- Pet Intensive Care Unit, Underwood, Australia
| | - A M Padula
- Padula Serums, Bairsndale, VIC, Australia
- Australian Venom Research Unit, University of Melbourne, Parkville, VIC, Australia
| |
Collapse
|
2
|
Smith VM, de Burgh SG, Jackson CM, Chambers MA, Page PC. Eight-month repellency and efficacy of an imidacloprid/flumethrin (Seresto ® ) collar against the eastern paralysis tick (Ixodes holocyclus) on cats. Aust Vet J 2021; 100:83-89. [PMID: 34734411 DOI: 10.1111/avj.13133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Revised: 09/02/2021] [Accepted: 09/26/2021] [Indexed: 11/29/2022]
Abstract
OBJECTIVE The objective of this study was to determine the repellency and efficacy of a 10% imidacloprid/4.5% flumethrin (Seresto® , Elanco) collar over an 8-month period against the eastern paralysis tick (Ixodes holocyclus) on cats. METHODS Two non-blinded, open gender, randomised, placebo-controlled pen studies were conducted, with 26 cats enrolled in each study. Prior to inclusion, cats were immunised with I. holocyclus holocyclotoxin. Cats were treated on Day 0 with either an imidacloprid/flumethrin or placebo collar. Tick infestations with 20 unfed adult female eastern paralysis ticks commenced on Day 7, and were repeated monthly for 8 months. Repellency was determined by comparing the mean number of attached ticks on imidacloprid/flumethrin treated cats, to placebo collar treated cats at 6 and 24 h post infestation. Efficacy was determined by comparing the mean number of live ticks on imidacloprid/flumethrin collar treated cats to placebo collar treated cats at 72 h post infestation. RESULTS Efficacy was 100% (P < 0.001) at 72 h, and repellency was greater than 96% (P < 0.001) at 24 h for every tick challenge in each of the two studies, from Day 7 to the final infestation at 8 months for imidacloprid/flumethrin collar treated cats. CONCLUSIONS In two pen studies, an imidacloprid/flumethrin collar controlled and repelled the eastern paralysis tick (I. holocyclus) on cats for 8-months. The marked repellency effect in addition to controlling tick paralysis would be beneficial in preventing tick bites and their sequelae.
Collapse
Affiliation(s)
- V M Smith
- Elanco Australasia Pty Ltd, 7 Eden Park Drive, Macquarie Park, New South Wales, 2113, Australia
| | - S G de Burgh
- Elanco Australasia Pty Ltd, 7 Eden Park Drive, Macquarie Park, New South Wales, 2113, Australia
| | - C M Jackson
- Invetus Pty Ltd, Yorklea, New South Wales, 2470, Australia
| | - M A Chambers
- Invetus Pty Ltd, Yorklea, New South Wales, 2470, Australia
| | - P C Page
- Elanco Australasia Pty Ltd, 7 Eden Park Drive, Macquarie Park, New South Wales, 2113, Australia
| |
Collapse
|
3
|
Wilkinson V, Takano K, Nichols D, Martin A, Holme R, Phalen D, Mounsey K, Charleston M, Kreiss A, Pye R, Browne E, Næsborg-Nielsen C, Richards SA, Carver S. Fluralaner as a novel treatment for sarcoptic mange in the bare-nosed wombat (Vombatus ursinus): safety, pharmacokinetics, efficacy and practicable use. Parasit Vectors 2021; 14:18. [PMID: 33407820 PMCID: PMC7789169 DOI: 10.1186/s13071-020-04500-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Accepted: 11/23/2020] [Indexed: 12/16/2022] Open
Abstract
Background Sarcoptic mange causes significant animal welfare and occasional conservation concerns for bare-nosed wombats (Vombatus ursinus) throughout their range. To date, in situ chemotherapeutic interventions have involved macrocytic lactones, but their short duration of action and need for frequent re-administration has limited treatment success. Fluralaner (Bravecto®; MSD Animal Health), a novel isoxazoline class ectoparasiticide, has several advantageous properties that may overcome such limitations. Methods Fluralaner was administered topically at 25 mg/kg (n = 5) and 85 mg/kg (n = 2) to healthy captive bare-nosed wombats. Safety was assessed over 12 weeks by clinical observation and monitoring of haematological and biochemical parameters. Fluralaner plasma pharmacokinetics were quantified using ultra-performance liquid chromatography and tandem mass spectrometry. Efficacy was evaluated through clinical assessment of response to treatment, including mange and body condition scoring, for 15 weeks after topical administration of 25 mg/kg fluralaner to sarcoptic mange-affected wild bare-nosed wombats (n = 3). Duration of action was determined through analysis of pharmacokinetic parameters and visual inspection of study subjects for ticks during the monitoring period. Methods for diluting fluralaner to enable ‘pour-on’ application were compared, and an economic and treatment effort analysis of fluralaner relative to moxidectin was undertaken. Results No deleterious health impacts were detected following fluralaner administration. Fluralaner was absorbed and remained quantifiable in plasma throughout the monitoring period. For the 25 mg/kg and 85 mg/kg treatment groups, the respective means for maximum recorded plasma concentrations (Cmax) were 6.2 and 16.4 ng/ml; for maximum recorded times to Cmax, 3.0 and 37.5 days; and for plasma elimination half-lives, 40.1 and 166.5 days. Clinical resolution of sarcoptic mange was observed in all study animals within 3–4 weeks of treatment, and all wombats remained tick-free for 15 weeks. A suitable product for diluting fluralaner into a ‘pour-on’ was found. Treatment costs were competitive, and predicted treatment effort was substantially lower relative to moxidectin. Conclusions Fluralaner appears to be a safe and efficacious treatment for sarcoptic mange in the bare-nosed wombat, with a single dose lasting over 1–3 months. It has economic and treatment-effort-related advantages over moxidectin, the most commonly used alternative. We recommend a dose of 25 mg/kg fluralaner and, based on the conservative assumption that at least 50% of a dose makes dermal contact, Bravecto Spot-On for Large Dogs as the most appropriate formulation for adult bare-nosed wombats. Graphical abstract ![]()
Collapse
Affiliation(s)
- Vicky Wilkinson
- School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, Tasmania, Australia.
| | - Kotaro Takano
- The University of the Sunshine Coast, 90 Sippy Downs Dr, Sippy Downs, QLD, Australia
| | - David Nichols
- Central Science Laboratory, University of Tasmania, Private Bag 74, Hobart, Tasmania, Australia
| | - Alynn Martin
- School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, Tasmania, Australia
| | - Roz Holme
- Cedar Creek Wombat Rescue Inc, PO Box 538, Cessnock, NSW, Australia
| | - David Phalen
- The University of Sydney, C01A, JI Shute, Camden, Sydney, NSW, Australia
| | - Kate Mounsey
- The University of the Sunshine Coast, 90 Sippy Downs Dr, Sippy Downs, QLD, Australia
| | - Michael Charleston
- School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, Tasmania, Australia
| | - Alexandre Kreiss
- Bonorong Wildlife Sanctuary, 593 Briggs Rd, Brighton, Tasmania, Australia
| | - Ruth Pye
- Bonorong Wildlife Sanctuary, 593 Briggs Rd, Brighton, Tasmania, Australia
| | - Elizabeth Browne
- School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, Tasmania, Australia
| | | | - Shane A Richards
- School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, Tasmania, Australia
| | - Scott Carver
- School of Natural Sciences, University of Tasmania, Private Bag 55, Hobart, Tasmania, Australia
| |
Collapse
|
4
|
Roeber F, Webster M. Protecting dogs and cats against the Australian paralysis tick, Ixodes holocyclus (Acari: Ixodidae): A review of the Australian acaricide registration process. CURRENT RESEARCH IN PARASITOLOGY & VECTOR-BORNE DISEASES 2021; 1:100054. [PMID: 35284866 PMCID: PMC8906080 DOI: 10.1016/j.crpvbd.2021.100054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Revised: 09/27/2021] [Accepted: 10/08/2021] [Indexed: 11/13/2022]
Abstract
Tick control is mainly achieved through the use of effective ectoparasiticides that can be either dermally or systemically distributed in/on the host. Before any acaricide can be legally made available to veterinarians and pet owners, it must demonstrate efficacy in a series of well-designed dose confirmation studies. The data generated during these studies are then reviewed by government regulators and used for the registration of the acaricide. In Australia, the most significant tick species is the Australian paralysis tick, Ixodes holocyclus. This three-host tick produces a potent neurotoxin (holocyclotoxin) that induces a rapidly ascending flaccid paralysis that can be fatal to companion animals and larger mammals such as cattle and horses. The Australian Pesticides and Veterinary Medicines Authority (APVMA) is the national Australian regulator which sets the data requirements for the registration of acaricides. This paper reviews the requirements set by the APVMA and puts them in direct context with the biology, distribution and reported acaricide susceptibility of I. holocyclus. An overview of acaricides currently registered in Australia for the control of I. holocyclus in dogs and cats, their reported efficacy data and the conduct of I. holocyclus efficacy trials are also provided. A review of the requirements for the conduct of acaricide efficacy trials for Ixodes holocyclus was undertaken. The requirements of the Australian government regulator were put in direct context with the biology of the species. The need for the inclusion of Far North Queensland ticks into tick studies needs to be further assessed. At present, there is no evidence of acaricide resistance in Ixodes holocyclus.
Collapse
|
5
|
Padula AM, Leister EM, Webster RA. Tick paralysis in dogs and cats in Australia: treatment and prevention deliverables from 100 years of research. Aust Vet J 2019; 98:53-59. [PMID: 31762008 DOI: 10.1111/avj.12891] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Revised: 10/20/2019] [Accepted: 10/21/2019] [Indexed: 02/02/2023]
Abstract
This review of tick paralysis caused by Ixodes holocyclus in Australia addresses the question: What are the key discoveries that have enabled effective treatment and prevention of tick paralysis in dogs and cats? Critical examination of 100 years of literature reveals that arguably only three achievements have advanced treatment and prevention of tick paralysis in animals. First, the most significant treatment advance was the commercial availability of tick antiserum in the 1930s. Hyperimmune serum currently remains the only specific anti-paralysis tick therapy available to veterinarians in Australia. Second, advances in veterinary critical care have increased survival rates of the most severely affected dogs and cats. Critical care advancements have been enabled through specialised veterinary hospitals that can provide appropriate care 24 h a day, and advanced training of veterinarians, veterinary nurses and technicians. Third, perhaps that biggest advance of all in the last 100 years of research has been the commercial availability of the isooxazoline class of acaricidal preventatives in Australia specifically for I. holocyclus. This highly effective class of preventatives offers long duration of action, low cost, spot-on or oral formulations and a low rate of adverse reactions. Animal owners and veterinarians now have the most useful tool of all - a reliable preventative. This review reveals the key events in research over the last 100 years and the tortuous pathway to delivering better treatment and preventative options for this enigmatic Australian parasite.
Collapse
Affiliation(s)
- A M Padula
- Australian Venom Research Unit, Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Melbourne, Parkville, Victoria, Australia.,Padula Serums Pty Ltd, Bairnsdale, Victoria, Australia
| | - E M Leister
- Pet Intensive Care Unit (Pet ICU), Underwood, Queensland, 4119, Australia
| | - R A Webster
- Pet Intensive Care Unit (Pet ICU), Underwood, Queensland, 4119, Australia
| |
Collapse
|